Last reviewed · How we verify
LEO 43204 Formulation 2 Dose XX
At a glance
| Generic name | LEO 43204 Formulation 2 Dose XX |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 43204 Formulation 2 Dose XX CI brief — competitive landscape report
- LEO 43204 Formulation 2 Dose XX updates RSS · CI watch RSS
- LEO Pharma portfolio CI